Pressure BioSciences, Inc. Share Price

Equities

PBIO

US74112E2081

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 15:01:22 02/05/2024 BST 5-day change 1st Jan Change
0.24 USD +1.14% Intraday chart for Pressure BioSciences, Inc. -2.04% -27.27%
Sales 2021 2M 160M Sales 2022 1.73M 139M Capitalization 15.89M 1.27B
Net income 2021 -20M -1.6B Net income 2022 -16M -1.28B EV / Sales 2021 16.4 x
Net Debt 2021 14.51M 1.16B Net Debt 2022 20.53M 1.64B EV / Sales 2022 21.1 x
P/E ratio 2021
-0.68 x
P/E ratio 2022
-0.81 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 98.82%
More Fundamentals * Assessed data
Dynamic Chart
Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing CI
Transcript : CBH International LLC, Pressure BioSciences, Inc. - M&A Call
Pressure BioSciences, Inc. completed the acquisition of CBH International LLC. CI
Pressure BioSciences, Inc. Receives Open Order Agreement from West Coast Manufacturing Partner CI
Pressure BioSciences, Inc. entered into a definitive agreement to acquire CBH International LLC. CI
Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies CI
Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food Safety CI
Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST Ambassador CI
Transcript : Pressure BioSciences, Inc., Q3 2023 Earnings Call, Nov 21, 2023
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Reports Q3 Revenue $413,009 MT
Pressure BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Pressure Biosciences Announces Exclusive Distribution Agreement with Bioscreen Instruments Pvt Ltd CI
Pressure BioSciences' Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately CI
Transcript : Pressure BioSciences, Inc., Q2 2023 Earnings Call, Aug 22, 2023
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Posts Q2 Revenue $511,800 MT
More news
1 day+1.14%
1 week-2.04%
Current month+36.99%
1 month+41.18%
3 months-7.69%
6 months-66.67%
Current year-27.27%
More quotes
1 week
0.21
Extreme 0.2139
0.27
1 month
0.17
Extreme 0.17
0.31
Current year
0.14
Extreme 0.14
0.50
1 year
0.14
Extreme 0.14
1.04
3 years
0.14
Extreme 0.14
4.98
5 years
0.14
Extreme 0.14
4.98
10 years
0.14
Extreme 0.14
17.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 31/07/78
Chief Tech/Sci/R&D Officer 70 23/04/06
Chief Tech/Sci/R&D Officer 59 02/04/06
Members of the board TitleAgeSince
Chief Executive Officer 73 31/07/78
Director/Board Member 75 02/07/12
Director/Board Member 71 07/02/13
More insiders
Date Price Change Volume
02/05/24 0.24 +1.14% 7 790
01/05/24 0.2373 -0.50% 54,170
30/04/24 0.2385 -0.50% 100
29/04/24 0.2397 +5.69% 7,100
26/04/24 0.2268 +3.09% 400

Delayed Quote OTC Markets, May 02, 2024 at 03:01 pm

More quotes
Pressure BioSciences, Inc. is engaged in providing broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. The Company's enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. The Company's BaroFold technology platform allows it to enter the bio-pharma contract services and GMP manufacturing equipment sector. It has also developed the scalable and pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be preserved using existing non-thermal technologies.
More about the company